Skip to content
WealthTicker

Compare

NAVs as of 20 Aug 2026

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) FundRegular · IDCW1 of 4 funds

Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (248 funds), which is the only comparison one fund can support.

Growth of ₹100 (rebased over the selected window)

Common period 16 Jul 201820 Aug 2026, limited by ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.

View as table
Growth of ₹100, sampled across the common period
DateICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) FundNifty 500
16 Jul 2018₹100.00₹100.00
19 Mar 2019₹101.52₹103.67
21 Nov 2019₹102.63₹105.21
24 Jul 2020₹139.09₹98.43
28 Mar 2021₹156.06₹131.61
29 Nov 2021₹168.89₹158.77
03 Aug 2022₹158.99₹161.17
06 Apr 2023₹144.95₹159.88
08 Dec 2023₹181.72₹202.61
11 Aug 2024₹234.34₹248.32
14 Apr 2025₹227.07₹224.81
17 Dec 2025₹233.64₹254.53
20 Aug 2026₹235.25₹254.71
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund compared on return, risk, benchmark-relative, cost and portfolio metrics, against the Sectoral/ Thematic median.
Metric
ICICI Prudential · Regular · IDCW
NAV ₹23.29
Very High risk
★★★★☆
Category median
Sectoral/ Thematic · 248 funds
-0.47%+3.54%
+12.31%+11.47%
+6.26%+9.70%
+10.32%
+11.15%+9.15%
+8.55%
+13.22%+12.10%
+12.84%+10.32%
+8.80%
Risk
15.67%15.91%
0.370.25
0.470.32
-29.44%-26.14%
Nifty 500
+2.10%-0.04%
0.850.98
92.1%98.3%
81.7%101.5%
2.08%2.38%
₹60.01Cr₹1,160Cr
Up to 1.00%
None
₹100
₹5.00K
78%42%
Sharmila D'silva
16 Jul 2018
35
59.3%
4.0%

Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.